跳至主要内容
临床试验/NCT02765217
NCT02765217已完成4 期

Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children: Prospective, Multi-center, Randomize, Parallel Group Placebo Controlled Clinical Trial

Eskisehir Osmangazi University1 个研究点 分布在 1 个国家目标入组 1,325 人开始时间: 2017年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
1,325
试验地点
1
主要终点
Incidence of antibiotic associated diarrhea

研究概览

简要总结

Recent studies showed that intestinal microbiota consist more than thousand bacteria, and these microorganisms play the role as balance and continuity of the anatomical and functional integrity gastrointestinal tract. Chronic diseases, nutritional factors, lifestyle factors and medications including antibiotics changes the host microbiota in short or long-term period. Antibiotics are the most commonly used drugs in pediatrics routine practice. Although frequency and severity of side effects alter the choice of drug, mild complications may be taken into consideration for treatment by a physician in the profit and loss balance. Our study group (PROBAGE Working Group) have been recently showed that Lactobacillus reuteri DSM 17938 reduced the duration of diarrhea in children with acute infectious diarrhea, and are safe and well-tolerated. In this study the investigators aim to evaluate the potential effect of Lactobacillus reuteri DSM 17938 on the prevention of antibiotic associated diarrhea in children.

详细描述

Recent studies showed that intestinal microbiota consist more than thousand bacteria, and these microorganisms play the role as balance and continuity of the anatomical and functional integrity gastrointestinal tract. Chronic diseases, nutritional factors, lifestyle factors and medications including antibiotics changes the host microbiota in short or long-term period. Antibiotics are the most commonly used drugs in pediatrics routine practice. Although frequency and severity of side effects alter the choice of drug, mild complications may be taken into consideration for treatment by a physician in the profit and loss balance.

Antibiotic-associated diarrhea is one of the side effects that occur during antibiotic use, the frequency varies according to region and antibiotic type. Aminopenicillins, cephalosporins and clindamycin antibiotics has been identified as the most affected group of antibiotic-associated diarrhea. Development of antibiotic associated diarrhea are associated with the intestinal microbiota balance , the mucosal integrity and changes of vitamin / mineral metabolism 3. Majority cases with antibiotic associated diarrhea admit with the complaints of abdominal crampy pain and diarrhea while pseudomembranous enterocolitis, in severe cases, even death have been reported. Antibiotic-associated diarrhea can be occur during antibiotic treatment but may seen at 2-3 weeks later after termination of treatment. Broad-spectrum antimicrobial agents have been related 11-40% of antibiotic associated diarrhea cases in children.

In Turkey there are no large studies on the frequency of antibiotic associated diarrhea in children, but antibiotics are the most commonly used drug classes in childhood. The use of broad-spectrum antibiotics, which creates more risk than narrow-spectrum antibiotics, and the highest risk have been observed during use of clindamycin, cephalosporins and fluoroquinolones. However, there is no consensus about which antibiotics which are high risk or which have significant negative impact on the microbiota. Antibiotic-associated diarrhea, has been shown to increase the growth of enteropathogens after antibiotic use.

In particular, Clostridium difficile (C. difficile) infections are the most common infections which related with antibiotic associated diarrhea 2. Although C. difficile diarrhea mostly occurs in adults and hospitalized immunocompromised patients, it can be seen in children.

C. difficile leads to mild diarrhea to pseudomembranous colitis according to toxins. C. difficile associated 10-20% of all antibiotic-associated diarrhea forms and can be seen until after eight weeks of treatment with antibiotics. Antibiotics disrupt the integrity of the normal colonic mucosa, affect carbohydrate metabolism as a result of antimicrobial activity in the colon leads to the development of osmotic diarrhea and pathogenic bacteria associated diarrhea. The slowing of the metabolism of carbohydrates results in the reduction of short-chain fatty acids in the intestinal lumen and cause accumulation of carbohydrates which can not be absorbed. Besides the harm normal microbiota have provided the protective barrier and intestinal system becomes sensitive to resistant microorganisms. Reduction of intestinal lumen and in the number of Bacteroides and Bifidobacteria strains of facultative anaerobes (Fusobacterium the Clostridia, Eubacteria) results in the increase. Antibiotic-associated diarrhea, alongside a negative effect on the quality of life of the host, the cost of treatment in patients hospitalized in the hospital and also negatively affects the length of stay.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
6 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Children receiving amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) due to acute otitis media or acute sinusitis

排除标准

  • Receiving antibiotic and/or probiotic, 8 weeks before the study
  • Chronic gastrointestinal system disorders
  • Congenital anomalies
  • Chronic diseases
  • Chemotherapy and radiotherapy
  • Pregnancy

研究组 & 干预措施

Study group 1

Experimental

Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (5 drops per day, same time with the first dose of antibiotics).

Study Group 1a will received L. reuteri for 10-14 days. Study Group 1b will received L. reuteri for 21 days.

干预措施: Lactobacillus reuteri DSM 17938 (Drug)

Study group 1

Experimental

Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (5 drops per day, same time with the first dose of antibiotics).

Study Group 1a will received L. reuteri for 10-14 days. Study Group 1b will received L. reuteri for 21 days.

干预措施: Amoxicillin-Clavulanic Acid (Drug)

Study group 2

Placebo Comparator

Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 5 drops per day, same time with the antibiotics) Study Group 2a will received placebo for 10-14 days. Study Group 2b will received placebo for 21 days.

干预措施: Placebo (Drug)

Study group 2

Placebo Comparator

Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 5 drops per day, same time with the antibiotics) Study Group 2a will received placebo for 10-14 days. Study Group 2b will received placebo for 21 days.

干预措施: Amoxicillin-Clavulanic Acid (Drug)

Study group 3

Experimental

Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (2 x 5 drops per day) Study Group 3a will received L. reuteri for 10-14 days. Study Group 3b will received L. reuteri for 21 days.

干预措施: Lactobacillus reuteri DSM 17938 (Drug)

Study group 3

Experimental

Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (2 x 5 drops per day) Study Group 3a will received L. reuteri for 10-14 days. Study Group 3b will received L. reuteri for 21 days.

干预措施: Amoxicillin-Clavulanic Acid (Drug)

Study group 4

Placebo Comparator

Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 2 x 5 drops per day, same time with the antibiotics) Study Group 4a will received placebo for 10-14 days. Study Group 4b will received placebo for 21 days.

干预措施: Placebo (Drug)

Study group 4

Placebo Comparator

Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 2 x 5 drops per day, same time with the antibiotics) Study Group 4a will received placebo for 10-14 days. Study Group 4b will received placebo for 21 days.

干预措施: Amoxicillin-Clavulanic Acid (Drug)

结局指标

主要结局

Incidence of antibiotic associated diarrhea

时间窗: 8 weeks time period after 1st day of antibiotic use

The frequency and consistency of the stools were recorded daily according to Bristol score; a score \<5 is described as normalization of stool and score equal or above 5 defined as diarrhea. Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug, Graded According to NCI CTCAE Version 3.0

次要结局

  • Incidence of antibiotic associated diarrhea during antibiotic treatment(10-14 days (depends on the antibiotic treatment))
  • The frequency of other gastrointestinal symptoms other than diarrhea during the study (will be evaluated using the Gastrointestinal Symptom Rating Score)(56 days)
  • Incidence of antibiotic associated diarrhea after antibiotic treatment(From 11-15th days of intervention to 56 days)
  • Evaluation of antibiotic-associated diarrhea in patients who developed diarrhea severity(56 days)

研究者

发起方
Eskisehir Osmangazi University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ener Cagri DINLEYICI

Professor in Pediatrics

Eskisehir Osmangazi University

研究点 (1)

Loading locations...

相似试验